Metabolic Modulators in Heart Disease: Past, Present, and Future

Canadian Journal of Cardiology

Volumn 33, Issue 7, 2017, Pages 838-849

  Lopaschuk, Gary D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BRANCHED CHAIN AMINO ACID; CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; FATTY ACID; GLUCOSE; INSULIN; ISOLEUCINE; KETONE; LACTIC ACID; LEUCINE; PERHEXILINE; POTASSIUM; TRIMETAZIDINE; VALINE;

AMINO ACID METABOLISM; ENERGY METABOLISM; ENERGY YIELD; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GLUCOSE OXIDATION; HEART FAILURE; HUMAN; INFUSION; ISCHEMIC HEART DISEASE; REVIEW; CARDIAC MUSCLE; HEART DISEASE; HEART MITOCHONDRION; METABOLISM; OXIDATION REDUCTION REACTION;

ENERGY METABOLISM; HEART DISEASES; HUMANS; MITOCHONDRIA, HEART; MYOCARDIUM; OXIDATION-REDUCTION;

EID: 85014428614     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2016.12.013     Document Type: Review

References (87)

1. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
2. McMurray, J.J., Pfeffer, M.A., Heart failure. Lancet 365 (2005), 1877–1889.
3. Roger, V.L., Go, A.S., Lloyd-Jones, D.M., et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 125 (2012), e2–e220.
4. Roger, V.L., Weston, S.A., Redfield, M.M., et al. Trends in heart failure incidence and survival in a community-based population. JAMA 292 (2004), 344–350.
5. Wang, G., Zhang, Z., Ayala, C., Wall, H.K., Fang, J., Costs of heart failure-related hospitalizations in patients aged 18 to 64 years. Am J Manag Care 16 (2010), 769–776.
6. Stanley, W.C., Recchia, F.A., Lopaschuk, G.D., Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85 (2005), 1093–1129.
7. Lopaschuk, G.D., Ussher, J.R., Folmes, C.D., Jaswal, J.S., Stanley, W.C., Myocardial fatty acid metabolism in health and disease. Physiol Rev 90 (2010), 207–258.
8. Jaswal, J.S., Keung, W., Wang, W., Ussher, J.R., Lopaschuk, G.D., Targeting fatty acid and carbohydrate oxidation - a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 1813 (2011), 1333–1350.
9. Martin, C., Schulz, R., Rose, J., Heusch, G., Inorganic phosphate content and free energy change of ATP hydrolysis in regional short-term hibernating myocardium. Cardiovasc Res 39 (1998), 318–326.
10. Folmes, C.D., Sowah, D., Clanachan, A.S., Lopaschuk, G.D., High rates of residual fatty acid oxidation during mild ischemia decrease cardiac work and efficiency. J Mol Cell Cardiol 47 (2009), 142–148.
11. Liu, B., Clanachan, A.S., Schulz, R., Lopaschuk, G.D., Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res 79 (1996), 940–948.
12. Liu, Q., Docherty, J.C., Rendell, J.C., Clanachan, A.S., Lopaschuk, G.D., High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol 39 (2002), 718–725.
13. Krahe, T., Schindler, R., Neubauer, S., et al. 31P-cardio-MR-spectroscopy in myocardial insufficiency [in German]. RoFo 159 (1993), 64–70.
14. Neubauer, S., Horn, M., Cramer, M., et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96 (1997), 2190–2196.
15. Casademont, J., Miro, O., Electron transport chain defects in heart failure. Heart Fail Rev 7 (2002), 131–139.
16. Weiss, R.G., Gerstenblith, G., Bottomley, P.A., ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc Natl Acad Sci U S A 102 (2005), 808–813.
17. Heusch, G., Libby, P., Gersh, B., et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383 (2014), 1933–1943.
18. Fukushima, A., Milner, K., Gupta, A., Lopaschuk, G.D., Myocardial energy substrate metabolism in heart failure: from pathways to therapeutic targets. Curr Pharm Res 21 (2015), 3654–3664.
19. Allard, M.F., Schonekess, B.O., Henning, S.L., English, D.R., Lopaschuk, G.D., Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol 267 (1994), H742–H750.
20. Zhang, L., Jaswal, J.S., Ussher, J.R., et al. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ Heart Fail 6 (2013), 1039–1048.
21. Mori, J., Alrob, O.A., Wagg, C.S., et al. ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4. Am J Physiol Heart Circ Physiol 304 (2013), H1103–H1113.
22. Zhabyeyev, P., Gandhi, M., Mori, J., et al. Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. Cardiovasc Res 97 (2013), 676–685.
23. Ingwall, J.S., Energy metabolism in heart failure and remodelling. Cardiovasc Res 81 (2009), 412–419.
24. Neubauer, S., The failing heart - an engine out of fuel. N Engl J Med 356 (2007), 1140–1151.
25. Aubert, G., Vega, R.B., Kelly, D.P., Perturbaton in the gene regulatory pathways controlling mitochondrial energy production in the failing heart. Biochim Biophys Acta 1833 (2013), 840–847.
26. Masoud, W.G., Ussher, J.R., Wang, W., et al. Failing mouse hearts utilize energy inefficiently and benefit from improved coupling of glycolysis and glucose oxidation. Cardiovasc Res 101 (2014), 30–38.
27. Bay, J., Kohlhass, M., Maack, C., Intracellular Na+ and cardiac metabolism. J Mol Cell Cardiol 61 (2013), 20–27.
28. Fillmore, N., Lopaschuk, G.D., Targeting mitochondrial oxidative metabolism as an approach to treat heart failure. Biochim Biophys Acta 1833 (2013), 857–865.
29. Liu, T., Takimoto, E., Dimaano, V.L., et al. Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure. Circ Res 115 (2014), 44–45.
30. Nakayama, H., Chen, X., Baines, C.P., et al. Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 117 (2007), 2431–2444.
31. Nakamura, T.Y., Iwata, Y., Arai, Y., Komamura, K., Wakabayashi, S., Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure. Circ Res 103 (2008), 891–899.
32. Cotter, D.G., Schugar, R.C., Crawford, P.A., Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol 304 (2013), H1060–H1076.
33. Aubert, G., Martin, O.J., Horton, J.L., et al. The failing heart relies on ketone bodies as a fuel. Circulation 133 (2016), 698–705.
34. Bedi, K.C. Jr., Snyder, N.W., Brandimarto, J., et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133 (2016), 706–716.
35. Horton, J.L., Martin, O.J., Lai, L., et al. Mitochondrial protein hyperacetylation in the failing heart. JCI Insight, 2, 2016, e84897.
36. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
37. Ferrannini, E., Mark, M., Mayoux, E., CV Protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
38. Mudaliar, S., Alloju, S., Henry, R.R., Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A Unifying Hypothesis. Diabetes Care 39 (2016), 1115–1122.
39. Lopaschuk, G.D., Verma, S., Empagliflozin's fuel hypothesis: not so soon. Cell Metab 24 (2016), 200–202.
40. Newgard, C.B., Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab 15 (2012), 606–614.
41. Jang, C., Oh, S.F., Wada, S., et al. A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat Med 22 (2016), 421–426.
42. Jewell, J.L., Russell, R.C., Guan, K.L., Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol 14 (2013), 133–139.
43. Sun, H., Olson, K.C., Gao, C., et al. Catabolic defect of branched-chain amino acids promotes heart failure. Circulation 133 (2016), 2038–2049.
44. Wang, W., Zhang, F., Xia, Y., et al. Defective branched chain amino acid catabolism contributes to cardiac dysfunction and remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol 311 (2016), H1160–H1169.
45. Sodi-Pallares, D., Testell, M.R., Fishleder, B.L., et al. Effects of an intravenous infusion of potassium-glucose-insulin solution on the electrocardiography signs of myocardial infarction. Am J Cardiol 9 (1962), 166–181.
46. Malmberg, K., Rydén, L., Hamsten, A., et al. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J 17 (1996), 1337–1344.
47. Díaz, R., Paolasso, E.A., Piegas, L.S., et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. Circulation 98 (1998), 2227–2234.
48. Mittra, B., Potassium, glucose, and insulin in treatment of myocardial infarction. Lancet 2 (1965), 607–609.
49. Fath-Ordoubadi, F., Beatt, K.J., Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 96 (1997), 1152–1156.
50. van der Horst, I.C., Zijlstra, F., van't Hof, A.W., et al. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 42 (2003), 784–791.
51. Goyal, A., Mehta, S.R., Díaz, R., et al. Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction. Circulation 120 (2009), 2429–2437.
52. Timmer, J.R., Ottervanger, J.P., de Boer, M.J., et al. Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction. J Am Coll Cardiol 45 (2005), 999–1002.
53. Díaz, R., Goyal, A., Mehta, S.R., et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA 298 (2007), 2399–2405.
54. McGarry, J.D., Takabayashi, Y., Foster, D.W., The role of malonyl-coa in the coordination of fatty acid synthesis and oxidation in isolated rat hepatocytes. J Biol Chem 253 (1978), 8294–8300.
55. Hajri, T., Han, X.X., Bonen, A., Abumrad, N.A., Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J Clin Invest 109 (2002), 1381–1389.
56. Lopaschuk, G.D., Wall, S.R., Olley, P.M., Davies, N.J., Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res 63 (1988), 1036–1043.
57. Wall, S.R., Lopaschuk, G.D., Glucose oxidation rates in fatty acid-perfused isolated working hearts from diabetic rats. Biochim Biophys Acta 1006 (1989), 97–103.
58. Schmidt-Schweda, S., Holubarsch, C., First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 99 (2000), 27–35.
59. Holubarsch, C.J., Rohrbach, M., Karrasch, M., et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (Etomoxir for the Recovery of Glucose Oxidation) study. Clin Sci (Lond) 113 (2007), 205–212.
60. Lee, L., Campbell, R., Scheuermann-Freestone, M., et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112 (2005), 3280–3288.
61. Pepine, C.J., Schang, S.J., Bemiller, C.R., Effects of perhexiline on coronary hemodynamic and myocardial metabolic responses to tachycardia. Circulation 49 (1974), 887–893.
62. Abozguia, K., Elliott, P., McKenna, W., et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122 (2010), 1562–1569.
63. Kantor, P.F., Lucien, A., Kozak, R., Lopaschuk, G.D., The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86 (2000), 580–588.
64. Peng, S., Zhao, M., Wan, J., et al. The efficacy of trimetazidine on stable angina pectoris: A meta-analysis of randomized clinical trials. Int J Cardiol 177 (2014), 780–785.
65. Fragasso, G., Palloshi, A., Puccetti, P., et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 48 (2006), 992–998.
66. Fragasso, G., Perseghin, G., De Cobelli, F., et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 27 (2006), 942–948.
67. Tuunanen, H., Engblom, E., Naum, A., et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 118 (2008), 1250–1258.
68. Ussher, J.R., Keung, W., Fillmore, N., et al. Treatment with the 3-ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice. J Pharmacol Exp Ther 349 (2014), 487–496.
69. Ussher, J.R., Fillmore, N., Keung, W., et al. Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice. Can J Cardiol 30 (2014), 940–944.
70. Gao, D., Ning, N., Niu, X., Hao, G., Meng, Z., Trimetazidine: a meta-analaysis of randomized controlled trials in heart failure. Heart 97 (2011), 278–286.
71. Stacpoole, P.W., The pharmacology of dichloroacetate. Metabolism 38 (1989), 1124–1144.
72. Kato, T., Niizuma, S., Inuzuka, Y., et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 3 (2010), 420–430.
73. Wargovich, T.J., MacDonald, R.G., Hill, J.A., et al. Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease. Am J Cardiol 61 (1988), 65–70.
74. Bersin, R.M., Wolfe, C., Kwasman, M., et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 23 (1994), 1617–1624.
75. Sankaralingam, S., Abo Alrob, O., Zhang, L., et al. Lowering body weight in obese mice with diastolic heart failure improves cardiac insulin sensitivity and function: implications for the obesity paradox. Diabetes 64 (2015), 1643–1645.
76. Peterson, L.R., Herrero, P., Schechtman, K.B., et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109 (2004), 2191–2196.
77. Lin, C.H., Kurup, S., Herrero, P., et al. Myocardial oxygen consumption change predicts left ventricular relaxation improvement in obese humans after weight loss. Obesity (Silver Spring) 19 (2011), 1804–1812.
78. Szczepaniak, L.S., Victor, R.G., Orci, L., Unger, R.H., Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res 101 (2007), 759–767.
79. Son, N.H., Yu, S., Tuinei, J., et al. PPARγ-induced cardiolipotoxicity in mice is ameliorated by PPARα deficiency despite increases in fatty acid oxidation. J Clin Invest 120 (2010), 3443–3454.
80. Sharma, S., Adrogue, J.V., Golfman, L., et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 18 (2004), 1692–1700.
81. Goldberg, I.J., Eckel, R.H., Abumrad, N.A., Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways. J Lipid Res 50:suppl (2009), S86–S90.
82. Coort, S.L., Willems, J., Coumans, W.A., et al. Sulfo-N-succinimidyl esters of long chain fatty acids specifically inhibit fatty acid translocase (FAT/CD36)-mediated cellular fatty acid uptake. Mol Cell Biochem 239 (2002), 213–219.
83. Ussher, J.R., Lopaschuk, G.D., Targeting malonyl CoA inhibition of mitochondrial fatty acid uptake as an approach to treat cardiac ischemia/reperfusion. Basic Res Cardiol 104 (2009), 203–210.
84. Dyck, J.R., Hopkins, T.A., Bonnet, S., et al. Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury. Circulation 114 (2006), 1721–1728.
85. Cheng, J.F., Huang, Y., Penuliar, R., et al. Discovery of potent and orally available malonyl-CoA decarboxylase inhibitors as cardioprotective agents. J Med Chem 49 (2006), 4055–4058.
86. Stanley, W.C., Morgan, E.E., Huang, H., et al. Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia. Am J Physiol Heart Circ Physiol 289 (2005), H2304–H2309.
87. Dyck, J.R., Cheng, J.F., Stanley, W.C., et al. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 94 (2004), e78–e84.